📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-29 16:14
122 analysed today
FollowTelegram
122
Today
149,523
All-time analysed
42,890
Positive
6,652
Negative
91,308
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
14 announcements match the current filters (relevance ≥ 5).
Indraprastha Medical Fixes Sep 18, 2026 Record Date for Rs 4.00/Share Dividend
Indraprastha Medical Corporation Limited has scheduled its 38th Annual General Meeting (AGM) for September 24, 2026, and fixed September 18, 2026, as the record date for a dividend of Rs 4.00 per share (40% on face value of Rs 10) for FY 2025-26. The proposed payout represents an aggregate distribution of approximately Rs 36.6 crore, which is ~39.8% of the company's TTM net profit of Rs 92 crore. At the current market price of Rs 368.1, the dividend corresponds to a yield of roughly 1.1%. Subject to shareholder approval at the AGM, the dividend will be disbursed within 30 days of declaration.
Confidence: HIGH
What changedThe company formally announced the AGM schedule, e-voting cut-off, and set the dividend record date to September 18, 2026.
Why it mattersConfirms capital return to shareholders with a payout of ~Rs 36.6 crore (~40% of TTM PAT), supported by low leverage (D/E of 0.05).
Proposed dividend per share: Rs 4.00 (40%)Record date: September 18, 2026AGM date: September 24, 2026Implied dividend yield: ~1.1%Estimated payout vs TTM PAT: ~39.8%
📅 Short termThe stock will trade cum-dividend until the trading session preceding the September 18, 2026 record date.
📈 Long termLimited; routine annual dividend distribution reflecting steady cash generation and high ROCE (36.0%).
Key Highlights
Proposed dividend of Rs 4.00 per equity share (40% of Rs 10 face value) for FY 2025-26
Record date and cut-off date fixed for Friday, September 18, 2026
38th Annual General Meeting to be held on Thursday, September 24, 2026
Payment to be disbursed within 30 days from date of shareholder approval
👀 What to Watch
Investors seeking to receive the dividend must hold shares before the ex-dividend date linked to the September 18, 2026 record date, and monitor the September 24 AGM for formal approval.
INDRAMEDCO Fixes Sep 18 Record Date for Rs 4/Share Dividend; AGM on Sep 24
Indraprastha Medical Corporation Limited has scheduled its 38th Annual General Meeting for Thursday, September 24, 2026, via Video Conferencing. The company has fixed Friday, September 18, 2026, as the Record Date for determining eligibility for a dividend of Rs 4.00 per equity share (40% on Rs 10 face value) for FY 2025-26. The cut-off date for remote e-voting is also set for September 18, 2026. Upon shareholder approval at the AGM, the dividend will be distributed within 30 days.
Confidence: HIGH
What changedThe company established the formal record date and AGM timeline for its FY 2025-26 dividend distribution.
Why it mattersThe Rs 4.00/share dividend represents an ~1.09% yield against the CMP of Rs 368.10, backed by a TTM EPS of Rs 10.03.
Dividend per share: Rs 4.00Dividend percentage: 40%Face value: Rs 10Record date: September 18, 2026AGM date: September 24, 2026
📅 Short termExpect regular ex-dividend price adjustments heading into the mid-September record date.
📈 Long termLimited; reflects routine annual capital return to shareholders.
Key Highlights
Dividend recommended at Rs 4.00 per share (40% on face value of Rs 10) for FY 2025-26
Record Date fixed as Friday, September 18, 2026, for dividend entitlement
Cut-off date for remote e-voting set for September 18, 2026
38th AGM to be held on Thursday, September 24, 2026, via VC/OAVM
Dividend to be paid within 30 days from approval date at the AGM
👀 What to Watch
Track the ex-dividend date prior to September 18, 2026, to qualify for the Rs 4.00/share dividend, and monitor voting outcomes following the AGM on September 24, 2026.
INDRAMEDCO Q1 PAT Up 8.5% YoY to ₹55.85 Cr; Revenue Grows 11.2%
Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) reported a steady Q1 FY27 with revenue from operations rising 11.2% YoY to ₹406.15 cr. Net profit (PAT) grew by 8.5% YoY to ₹55.85 cr, while Profit Before Tax (PBT) saw a 9.5% increase to ₹74.82 cr. The company has fixed September 18, 2026, as the record date for the FY26 dividend and the upcoming Annual General Meeting. Operating margins faced slight pressure as professional charges to doctors rose 13.6% YoY, outpacing revenue growth.
Confidence: HIGH
What changedThe company released its unaudited financial results for the first quarter of FY27 and announced the schedule for its Annual General Meeting and dividend record date.
Why it mattersThe results demonstrate double-digit top-line growth, maintaining the company's 9-12% growth trajectory despite rising costs for medical professionals and materials.
Q1 Revenue from Operations: ₹406.15 crQ1 Profit After Tax: ₹55.85 crQ1 Revenue vs FY26 Annual Revenue: 27.4%Professional Charges to Doctors: ₹111.15 crDividend Record Date: 18th September, 2026
📅 Short termThe stock is likely to see neutral-to-positive sentiment following steady earnings growth and the confirmation of the dividend record date.
📈 Long termThe company continues to leverage the Apollo brand in the NCR region; long-term value depends on maintaining ARPOB growth and managing rising doctor professional fees.
⚠ Risk flags
- Rising professional charges to doctors (up 13.6% YoY) exceeding revenue growth rate
- Geographic concentration in the NCR region
Key Highlights
Revenue from operations increased to ₹406.15 cr in Q1 FY27 from ₹365.06 cr in Q1 FY26.
Net Profit (PAT) for the quarter stood at ₹55.85 cr, up from ₹51.46 cr in the previous year's corresponding quarter.
Professional charges to doctors, a key expense, rose by 13.6% YoY to ₹111.15 cr.
Basic and Diluted EPS for the quarter improved to ₹6.09 from ₹5.61 YoY.
Record date for dividend and the 38th AGM (scheduled for Sept 24) is fixed as September 18, 2026.
👀 What to Watch
Investors should monitor the upcoming AGM on September 24, 2026, for management commentary on bed occupancy rates and the impact of international patient volumes on margins.
₹55.85 Cr Q1 PAT; Indraprastha Medical Sets Sep 18 as Dividend Record Date
Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) reported a steady Q1 FY27 with revenue from operations growing 11.2% YoY to ₹406.15 cr. Net profit for the quarter increased by 8.5% to ₹55.85 cr, up from ₹51.46 cr in the year-ago period. The Board has fixed September 18, 2026, as the record date for the FY26 dividend and the upcoming 38th Annual General Meeting. Operational margins remained healthy with a Profit Before Tax (PBT) of ₹74.82 cr, representing an 18.4% margin on total income.
Confidence: HIGH
What changedThe company has released its Q1 FY27 financial results showing continued growth and formalized the timeline for its annual dividend distribution.
Why it mattersThe results demonstrate the company's ability to maintain double-digit revenue growth in the competitive NCR healthcare market while managing rising operational costs.
Q1 FY27 Revenue: ₹406.15 crQ1 FY27 PAT: ₹55.85 crYoY Revenue Growth: 11.2%Record Date: 18-Sep-2026Q1 EPS: ₹6.09
📅 Short termThe stock is likely to see neutral-to-positive sentiment driven by steady earnings growth and the upcoming dividend record date.
📈 Long termThe company remains a stable healthcare play in the NCR region with high ROCE (36%), though long-term growth depends on bed turnover efficiency and high-margin elective surgeries.
⚠ Risk flags
- Geographic concentration in the NCR region
- Rising professional fees for doctors impacting margins
- Regulatory price controls on medical procedures
Key Highlights
Revenue from operations increased 11.2% YoY to ₹406.15 cr in Q1 FY27.
Net Profit (PAT) rose 8.5% YoY to ₹55.85 cr for the quarter ended June 2026.
Record date for dividend and 38th AGM fixed for September 18, 2026.
Professional charges to doctors, a key cost component, rose 13.6% YoY to ₹111.15 cr.
Earnings Per Share (EPS) for the quarter stood at ₹6.09 compared to ₹5.61 in Q1 FY26.
👀 What to Watch
Investors should track the dividend payout ratio following the AGM on September 24, 2026. Monitor the trend in 'Professional charges to doctors' as it remains the largest expense head at 27% of revenue.
8.5% PAT growth to ₹55.85 cr in Q1 FY27; Record Date for Dividend set for Sept 18
Indraprastha Medical Corporation reported a steady Q1 FY27 with revenue from operations growing 11.3% YoY to ₹406.15 cr. Net profit (PAT) increased by 8.5% YoY to ₹55.85 cr, resulting in an EPS of ₹6.09 compared to ₹5.61 in the previous year's quarter. The Board has fixed September 18, 2026, as the record date for the FY26 dividend. While revenue grew, professional charges to doctors rose 13.6% YoY to ₹111.15 cr, slightly impacting margin expansion.
Confidence: HIGH
What changedThe company has transitioned into the new fiscal year (FY27) with positive growth in both top-line and bottom-line figures, alongside formalizing the dividend timeline for the previous year.
Why it mattersThe results confirm the company's ability to maintain growth momentum in the NCR healthcare market, though the rising cost of professional medical services remains a key expense to track against revenue growth.
Revenue (Q1 FY27): ₹406.15 crPAT (Q1 FY27): ₹55.85 crYoY Revenue Growth: 11.26%Professional Charges to Doctors: ₹111.15 crRecord Date: 18th September 2026
📅 Short termThe stock is likely to see neutral-to-positive sentiment as the earnings show steady growth and provide clarity on the dividend payout schedule.
📈 Long termThe company maintains a strong ROCE (36%) and low debt, but long-term growth depends on its ability to manage geographic concentration in NCR and rising medical professional costs.
⚠ Risk flags
- Rising professional charges to doctors (up 13.6% YoY)
- Geographic concentration in the NCR region
- Regulatory price control risks on medical procedures
Key Highlights
Revenue from operations increased 11.26% YoY to ₹406.15 cr in Q1 FY27.
Profit After Tax (PAT) grew 8.53% YoY to ₹55.85 cr from ₹51.46 cr.
Professional charges to doctors rose to ₹111.15 cr, accounting for 27.4% of total revenue.
Record date for FY26 dividend and 38th AGM fixed for September 18, 2026.
Total comprehensive income for the period stood at ₹58.10 cr, up from ₹55.94 cr YoY.
👀 What to Watch
Investors should monitor management commentary during the AGM on September 24, 2026, specifically regarding bed occupancy trends and the impact of rising doctor professional fees on long-term margins.
ICRA Reaffirms [ICRA]AA (Stable) Rating for Indraprastha Medical Corp's Rs 162.50 Cr Facilities
ICRA Limited has reaffirmed the credit ratings for Indraprastha Medical Corporation Limited (Indraprastha Apollo Hospitals), maintaining a strong investment-grade profile. The long-term rating for Rs 132.50 crore in facilities is reaffirmed at [ICRA]AA with a Stable outlook, while short-term facilities of Rs 30 crore are maintained at [ICRA]A1+. The total rated amount of Rs 162.50 crore includes a significant proposed term loan of Rs 92.50 crore. This reaffirmation underscores the company's continued financial stability and creditworthiness in the healthcare sector.
Key Highlights
Long-term rating reaffirmed at [ICRA]AA (Stable) for Rs 132.50 crore in bank facilities.
Short-term rating reaffirmed at [ICRA]A1+ for Rs 30.00 crore non-fund based limits.
Total bank facilities rated by ICRA amount to Rs 162.50 crore.
The rating includes a proposed term loan of Rs 92.50 crore for future capital requirements.
Facilities are spread across major lenders including ICICI Bank, PNB, and HDFC Bank.
👀 What to Watch
Investors should view this reaffirmation as a confirmation of the company's robust financial health and low credit risk. No immediate portfolio changes are necessary as the credit profile remains stable and high-grade.
Indraprastha Medical Corp Recommends Final Dividend of Rs 4 Per Share
The Board of Directors of Indraprastha Medical Corporation Limited, at its meeting on May 12, 2026, has recommended a final dividend of Rs. 4 per equity share. This recommendation is subject to the approval of shareholders at the upcoming Annual General Meeting. The company also clarified that it does not qualify as a 'Large Corporate' under SEBI's specific regulatory framework. The board meeting concluded at 4:35 p.m. following a session that began at 3:00 p.m.
Key Highlights
Recommended a Final Dividend of Rs. 4 per equity share for the financial year.
Board meeting held on May 12, 2026, concluded at 4:35 p.m.
Confirmed non-applicability of 'Large Corporate' (LC) criteria per SEBI circulars.
Dividend payout is subject to shareholder approval at the next AGM.
👀 What to Watch
Investors seeking regular income should monitor the upcoming record date to ensure eligibility for the Rs. 4 per share dividend. The stock remains a steady dividend-payer in the healthcare services sector.
Indraprastha Medical Corp Approves FY26 Results; Confirms Non-Large Corporate Status
Indraprastha Medical Corporation Limited (Indraprastha Apollo Hospitals) has concluded its board meeting to approve financial results for the fiscal year ended March 31, 2026. The company officially declared that it does not meet the SEBI criteria for 'Large Corporate' (LC) status, which simplifies certain regulatory and borrowing disclosures. The board meeting was held on May 12, 2026, lasting approximately 95 minutes. This filing serves as the formal submission of the year-end financial performance to the stock exchanges.
Key Highlights
Board meeting concluded on May 12, 2026, for the approval of financial results for the period ended March 31, 2026.
Company confirmed it does not fulfill criteria for 'Large Corporate' status under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144.
The board meeting commenced at 3:00 p.m. and concluded at 4:35 p.m.
The submission includes Annexures A, B, and C representing the detailed financial statements and audit reports.
👀 What to Watch
Investors should examine the detailed financial annexures to evaluate the company's year-on-year growth and profitability margins. The non-LC status suggests the company's outstanding long-term borrowings are below the INR 100 crore threshold or it does not meet the market cap criteria.
Indraprastha Medical Approves Q3 Results; Appoints Harsh Pati Singhania to Board for 5-Year Term
Indraprastha Medical Corporation (Indraprastha Apollo) has approved its financial results for the quarter and nine months ended December 31, 2025. A significant update was provided regarding the ongoing land lease litigation for the Sarita Vihar hospital, with the Delhi Government filing a new affidavit in the Supreme Court. The company also announced major board changes, including the appointment of high-profile industrialist Harsh Pati Singhania as an Independent Director. Additionally, three existing independent directors were re-appointed for five-year terms, ensuring continuity in governance.
Key Highlights
Approved un-audited financial results for the quarter and nine-month period ended December 31, 2025.
Noted a new affidavit filed by the Delhi Government in the Supreme Court regarding the Sarita Vihar hospital land lease matter.
Appointed Mr. Harsh Pati Singhania (CMD of JK Paper) as an Independent Director for a 5-year term until February 2031.
Re-appointed three Independent Directors (Salil Singhal, Vineeta Rai, and Madhumita Ganguli) for second 5-year terms.
The board meeting concluded on February 3, 2026, after a session lasting over two hours.
👀 What to Watch
Investors should closely monitor the Supreme Court proceedings regarding the land lease, as this remains a critical legal overhang for the company's primary asset. The addition of experienced industrial leadership to the board is a positive development for corporate governance.
Indraprastha Medical Appoints Harsh Pati Singhania to Board; Updates on Land Lease Legal Case
Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) has approved its Q3 FY26 financial results and announced significant board changes. Mr. Harsh Pati Singhania, CMD of JK Paper, has been appointed as an Independent Director for a five-year term effective February 3, 2026. The company also re-appointed three other Independent Directors, including Mr. Salil Singhal and Ms. Madhumita Ganguli, for second five-year terms. Additionally, the company is reviewing a new affidavit filed by the Delhi Government in the Supreme Court regarding the ongoing land lease and free patient treatment matter.
Key Highlights
Approved unaudited financial results for the quarter and nine months ended December 31, 2025
Appointed Mr. Harsh Pati Singhania as Independent Director for a 5-year term ending February 2031
Re-appointed three Independent Directors for 5-year terms to ensure board continuity
Noted a new affidavit from the Govt. of NCT of Delhi regarding the Sarita Vihar hospital land lease litigation
The ongoing 'Free Patient Matter' remains under consideration by the Hon'ble Supreme Court of India
👀 What to Watch
Investors should closely monitor the Supreme Court proceedings regarding the land lease and free patient matter as it represents a significant operational risk. The addition of high-profile industrial leaders to the board is a positive signal for corporate governance.
Indraprastha Medical Appoints Harsh Pati Singhania to Board; Approves Q3 FY26 Results
Indraprastha Medical Corporation (Indraprastha Apollo) has approved its Q3 FY26 financial results and announced a significant board refresh. Mr. Harsh Pati Singhania, CMD of JK Paper, has been appointed as an Independent Director for a five-year term. Additionally, three existing independent directors, including Ms. Vineeta Rai and Mr. Salil Singhal, were re-appointed for second five-year terms. The company also disclosed a legal update regarding an affidavit filed by the Delhi Government in the ongoing Supreme Court case concerning the hospital's land lease and free patient treatment obligations.
Key Highlights
Appointment of Mr. Harsh Pati Singhania as Non-Executive Independent Director for a 5-year term (2026-2031).
Re-appointment of Ms. Vineeta Rai and Mr. Salil Singhal for second 5-year terms effective February 8, 2026.
Approval of un-audited financial results for the quarter and nine months ended December 31, 2025.
Ongoing legal monitoring of the Supreme Court case (SLP 29482/2009) regarding the hospital's land lease in Sarita Vihar.
👀 What to Watch
The addition of high-profile industrial leadership to the board is a positive for governance, but investors should primarily focus on the upcoming Q3 earnings details and the eventual Supreme Court ruling on the land lease matter.
Indraprastha Medical Approves Q3 Results, Appoints Harsh Pati Singhania as Independent Director
Indraprastha Medical Corporation Limited (Indraprastha Apollo) has approved its Q3 FY26 financial results and announced several key board appointments. Mr. Harsh Pati Singhania, CMD of JK Paper, joins as an Independent Director, while three others, including Mr. Salil Singhal, have been re-appointed for five-year terms. The company is also monitoring a legal update involving an affidavit filed by the Delhi Government in the Supreme Court regarding land lease and free patient treatment. These developments highlight a focus on governance and ongoing regulatory challenges.
Key Highlights
Approved un-audited financial results for the quarter and nine months ended December 31, 2025
Appointed Mr. Harsh Pati Singhania (CMD, JK Paper) as Independent Director for a 5-year term starting Feb 2026
Re-appointed three Independent Directors, including Mr. Salil Singhal, for 5-year terms
Noted a new affidavit filed by the Delhi Government in the Supreme Court regarding the 'Free Patient Matter' and land lease
👀 What to Watch
Investors should review the detailed Q3 financial performance once published and closely monitor the Supreme Court proceedings regarding the land lease, as it represents a significant regulatory risk.
Indraprastha Medical Appoints Harsh Pati Singhania as Director; Re-appoints 3 Independent Directors
Indraprastha Medical Corporation has appointed Mr. Harsh Pati Singhania, CMD of JK Paper, as an Independent Director for a five-year term starting February 3, 2026. The board also approved the re-appointment of three other Independent Directors—Mr. Salil Singhal, Ms. Vineeta Rai, and Ms. Madhumita Ganguli—for subsequent five-year terms. Additionally, the company noted a new affidavit filed by the Delhi Government regarding a long-standing legal matter (SLP 29482/2009) concerning free patient care and the hospital's land lease. While Q3 FY26 financial results were approved, specific figures were not disclosed in this announcement.
Key Highlights
Appointment of Mr. Harsh Pati Singhania (CMD, JK Paper) as Independent Director for a 5-year term until Feb 2031.
Re-appointment of three Independent Directors for 5-year terms to ensure board continuity and governance.
Update on pending Supreme Court matter regarding land lease and free patient care obligations with the Delhi Government.
Approval of un-audited financial results for the quarter and nine months ended December 31, 2025.
👀 What to Watch
Investors should monitor the Supreme Court's decision on the land lease and free patient care matter as it remains a key regulatory risk. The induction of high-profile industry leaders to the board is a positive sign for long-term strategic oversight.
Indraprastha Medical Approves Q3 Results; Appoints Harsh Pati Singhania to Board
Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) approved its Q3 FY26 financial results and addressed a critical legal update regarding its land lease. The company noted a new affidavit filed by the Delhi Government in the Supreme Court concerning the 'Free Patient Matter' and land lease terms. On the governance front, the board appointed Mr. Harsh Pati Singhania, CMD of JK Paper, as an Independent Director for five years. Additionally, three existing Independent Directors were re-appointed for second five-year terms, ensuring leadership continuity.
Key Highlights
Approved un-audited financial results for the quarter and nine months ended December 31, 2025.
Appointed Mr. Harsh Pati Singhania as an Independent Director for a 5-year term effective February 3, 2026.
Re-appointed three Independent Directors (Salil Singhal, Vineeta Rai, and Madhumita Ganguli) for 5-year terms.
Noted a new affidavit from the Delhi Government in the ongoing Supreme Court case (SLP 29482/2009) regarding the hospital's land lease.
👀 What to Watch
Investors should closely monitor the Supreme Court's upcoming deliberations on the land lease and free patient matter, as this remains a significant regulatory overhang. The addition of high-profile industrial leadership to the board is a positive indicator for corporate governance.
